Mosaic ImmunoEngineering, Inc. (CPMV)
| Previous Close | 0.6000 |
| Open | 0.6000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.6000 - 0.6000 |
| 52 Week Range | 0.3020 - 1.0000 |
| Volume | |
| Avg. Volume | 506 |
| Market Cap | 4.345M |
| Beta (5Y Monthly) | -1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings Date | May 12, 2024 - May 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 02, 2007 |
| 1y Target Est | N/A |
GlobeNewswireOncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. (OTCPK: CPMV) (“Mosaic”) under which Mosaic will acquire rights to Oncotelic’s clinical-stage necroptosis cancer therapies. Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death re
ACCESSWIREMosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April ...
